Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.36 |
| ▸ | HPGD | P15428 | 4/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.34 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.34 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.34 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 4/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.33 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.32 |
| ▸ | RGS12 | O14924 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29398201 | 1.00 | LMNA (0.37) | LMNASMN1; SMN2HPGDHSD17B10ALDH1A1 | |
| SCHEMBL20384698 | 1.00 | LMNA (0.37) | LMNASMN1; SMN2HPGDHSD17B10ALDH1A1 | |
| Hydrochloric Acid SCHEMBL30767122 | 0.99 | LMNA (0.36) | LMNASMN1; SMN2HPGDHSD17B10ALDH1A1 | |
| SCHEMBL10340552 | 0.92 | LMNA (0.34) | LMNASMN1; SMN2HPGDHSD17B10ALDH1A1 | |
| SCHEMBL17072479 | 0.90 | LMNA (0.33) | LMNASMN1; SMN2HPGDHSD17B10ALDH1A1 | |
| SCHEMBL15752290 | 0.89 | LMNA (0.33) | LMNASMN1; SMN2HPGDHSD17B10ALDH1A1 | |
| SCHEMBL29351145 | 0.89 | LMNA (0.38) | LMNASMN1; SMN2HPGDHSD17B10ALDH1A1 | |
| SCHEMBL321113 | 0.89 | LMNA (0.38) | LMNASMN1; SMN2HPGDHSD17B10ALDH1A1 | |
| SCHEMBL159766 | 0.89 | SMN1; SMN2 (0.39) | LMNASMN1; SMN2HPGDHSD17B10ALDH1A1 | |
| SCHEMBL8610607 | 0.89 | LMNA (0.38) | LMNASMN1; SMN2HPGDHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1998 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4729617-A1 | APTAMER TARGETING CD25, DRUG CONJUGATE COMPRISING SAME, AND USE THEREOF | Aptamer Sciences Inc. (KR) | 2026-04-22 | — | — | EP | claimed |
| US-20250325717-A1 | ANTI-NUCLEOPHOSMIN 1 ANTIBODY AND ANTIBODY CONJUGATE COMBINATION THERAPIES | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-10-23 | — | — | US | claimed |
| US-20250313647-A1 | MUTANT AND MISLOCALIZED CELL SURFACE NUCLEOPHOSMIN 1 AS A DIAGNOSTIC AND THERAPEUTIC TARGET OF HUMAN DISEASE | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-10-09 | — | — | US | claimed |
| US-20250302762-A1 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | UNIVERSITY OF CONNECTICUT (US) | 2025-10-02 | — | — | US | claimed |
| US-12428477-B2 | Antibody-drug conjugates comprising anti-TM4SF1 antibodies and methods of using the same | ANGIEX, INC. (US) | 2025-09-30 | — | — | US | claimed |
| WO-2025083205-A1 | DRUG COMBINATION COMPRISING ANTI-CD37 ANTIBODY MAYTANSINE CONJUGATE AND BCL2 INHIBITOR OR PI3K INHIBITOR | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2025-04-24 | — | — | WO | claimed |
| US-20250127915-A1 | ANTI-CLDN-18.2 ANTIBODY-DRUG CONJUGATE AND USE THEREOF | SHANGHAI JUNSHI BIOSCIENCES CO LTD (CN) | 2025-04-24 | — | — | US | claimed |
| EP-4514857-A2 | ANTI-NUCLEOPHOSMIN 1 ANTIBODY AND ANTIBODY CONJUGATE COMBINATION THERAPIES | The Children's Medical Center Corporation (US) | 2025-03-05 | — | — | EP | claimed |
| EP-4514858-A2 | MUTANT AND MISLOCALIZED CELL SURFACE NUCLEOPHOSMIN 1 AS A DIAGNOSTIC AND THERAPEUTIC TARGET OF HUMAN DISEASE | The Children's Medical Center Corporation (US) | 2025-03-05 | — | — | EP | claimed |
| EP-4504732-A2 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | University of Connecticut (US) | 2025-02-12 | — | — | EP | claimed |
| EP-1806365-A1 | Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them | Boehringer Ingelheim International GmbH (DE) | 2007-07-11 | — | — | EP | claimed |
| US-7192586-B2 | Topical administration of an anti-PSMA antibody alone or conjugated to a cytotoxic moiety to the extracellular domain of human prostate specific membrane antigen (PSMA); anti-proliferative agents and - carcinogenic agents | CORNELL RESEARCH FOUNDATION, INC. (US) | 2007-03-20 | — | — | US | claimed |
| US-7045605-B2 | Modified antibodies to prostate-specific membrane antigen and uses thereof | CORNELL RESEARCH FOUNDATION, INC. (US) | 2006-05-16 | — | — | US | claimed |
| US-20060062793-A1 | Modified antibodies to prostate-specific membrane antigen and uses thereof | US ARMY, SECRETARY OF THE ARMY | 2006-03-23 | — | — | US | claimed |
| EP-1390370-A4 | METHODS FOR PREPARATION OF CYTOTOXIC CONJUGATES OF MAYTANSINOIDS AND CELL BINDING AGENTS | IMMUNOGEN INC (US) | 2005-07-06 | — | — | EP | claimed |
| US-20040213791-A1 | Modified antibodies to prostate-specific membrane antigen and uses thereof | THE UNITED STATES GOVERNMENT SECRETARY OF THE ARMY ARMY MEDICAL RESEARCH AND MATERIEL COMMAND | 2004-10-28 | — | — | US | claimed |
| EP-1390370-A1 | METHODS FOR PREPARATION OF CYTOTOXIC CONJUGATES OF MAYTANSINOIDS AND CELL BINDING AGENTS | Immunogen, Inc. (US) | 2004-02-25 | — | — | EP | claimed |
| US-20030055226-A1 | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents | IMMUNOGEN, INC. | 2003-03-20 | — | — | US | claimed |
| WO-2002098883-A1 | METHODS FOR PREPARATION OF CYTOTOXIC CONJUGATES OF MAYTANSINOIDS AND CELL BINDING AGENTS | IMMUNOGEN, INC. (US) | 2002-12-12 | — | — | WO | claimed |
| US-6441163-B1 | COUPLING MAYTANSINOIDS HAVING DISULFIDE LINKER BEARING REACTIVE MOIETY TO SUCH AS ANTIBODIES WITHOUT PRIOR MODIFICATION OF SAID ANTIBODY; ONE-STEP, HIGH YIELD, LOWER COST | IMMUNOGEN, INC. | 2002-08-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12428477-B2 | Antibody-drug conjugates comprising anti-TM4SF1 antibodies and methods of using the same | TM9SF4, TM9SF2, TM9SF3 | LMNA 2873/4885SMN1; SMN2 1960/4885HPGD 4380/4885 |
| US-20030055226-A1 | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents | SPR, SELPLG, CD2BP2 | LMNA 2357/4885SMN1; SMN2 1810/4885HPGD 1406/4885 |
| US-20250302762-A1 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | JAK2, JAK1, CHMP4B | LMNA 1531/4885SMN1; SMN2 84/4885HPGD 3471/4885 |
| US-20250127915-A1 | ANTI-CLDN-18.2 ANTIBODY-DRUG CONJUGATE AND USE THEREOF | EPCAM, SLC22A8, SLC17A5 | LMNA 1649/4885SMN1; SMN2 3127/4885HPGD 2609/4885 |
| US-20060062793-A1 | Modified antibodies to prostate-specific membrane antigen and uses thereof | KLK3, FOLH1, PSMA6 | LMNA 1893/4885SMN1; SMN2 3987/4885HPGD 2644/4885 |
| US-20040213791-A1 | Modified antibodies to prostate-specific membrane antigen and uses thereof | KLK3, FOLH1, PSMA6 | LMNA 1893/4885SMN1; SMN2 3987/4885HPGD 2644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.